Accurate Clinical Research

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Rheumatoid arthritis3 trials
• Crohn's disease1 trial
• Lupus (SLE)1 trial
• Obesity1 trial
• Osteoarthritis1 trial
• Psoriasis1 trial
• Psoriatic arthritis1 trial

Phase

• Phase 24 trials
• Phase 31 trial
• Phase 41 trial

Status

• Active, not recruiting5 trials
• Completed3 trials

Lead sponsor

• Aqtual, Inc.1 trial
• Eli Lilly and Company1 trial
• Janssen Research & Development, LLC1 trial
• OrthoTrophix, Inc1 trial
• Rhythm Pharmaceuticals, Inc.1 trial
• and 3 more

Running trials

• Active, not recruiting

  53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

  NCT06865079· Phase 2· OrthoTrophix, Inc· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  NCT06671483· Phase 3· Takeda· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

  NCT06559163· Phase 2· Zenas BioPharma (USA), LLC· Source

• Active, not recruiting

  Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD

  NCT05936970· Aqtual, Inc.· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

Closed trials

• Completed

  DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

  NCT04963231· Phase 2· Rhythm Pharmaceuticals, Inc.· Source

• Completed

  The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

  NCT03631225· Sequenom, Inc.· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Eli Lilly and Company· Source